

ASX/Media Release

5 December 2018

Updated investor presentation

Philadelphia PA and Sydney Australia, 5 December 2018: Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) is pleased to release an updated investor presentation, to be presented to investors, strategic partners and brokers in Canada this week. This presentation provides an overview of Botanix’s key investment highlights; Permetrex™ delivery technology; acne, atopic dermatitis, psoriasis and antimicrobial programs; and other key upcoming activities.

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Founder & Executive Director
+1 215 767 4184

mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital
P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Julia Maguire
The Capital Network

P: +61 419 815 386

julia@thecapitalnetwork.com.au

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12 week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical trial in June 2018 with completion expected in mid-2019. The Phase 1b BTX 1204 atopic dermatitis patient study concluded in June 2018 and preparation is underway for a Phase 2 clinical trial. The Phase 1b BTX 1308 psoriasis patient study commenced in September 2018.

For more information on Botanix, please visit www.botanixpharma.com

Botanix Overview

Canada

December 2018

Key investment highlights

Botanix is a global dermatology company delivering synthetic cannabinoids topically for the treatment of skin diseases



Dermatology
focused

Advanced clinical programs targeting multi-billion dollar prescription markets for acne, atopic dermatitis and psoriasis



De-risked drug
active

Products use a synthetic form of cannabidiol with a proven safety profile (Epidiolex® recently approved by FDA) – increases the probability of success



Clinical stage

Successful clinical data from acne and atopic dermatitis patient studies shows industry leading performance, after only 4 weeks of treatment



Novel
approach

Novel skin delivery technology, Permetrex™ - enhances delivery of cannabidiol into the skin compared to traditional formulation approaches




Experienced
team

Predominantly US based leadership team with 20+ FDA approvals between them and extensive dermatology industry experience

Permetrex™ skin delivery technology


Proprietary Permetrex™ technology delivers high doses of drug into the layers of the skin without use of permeation enhancers, preservatives, or the use of irritating alcohol/petrolatum additives



Botanix holds the exclusive rights to utilise Permetrex™ for all drugs that treat skin diseases

Permetrex™ technology enables superior delivery of cannabidiol






Permetrex™ delivers more much more cannabidiol (CBD) into the target layers of the skin, even though the CBD concentration of the BTX 1503 formulation is only 25% to 50% the concentration of alternative formulations



1. Botanix Pharmaceuticals data on file

Clinical programs with near term milestones

Phase 2 acne and atopic dermatitis programs supported by exciting development pipeline, with Permetrex™ collaborations to augment revenue and news flow

Product candidate		Indication	Pre-clin	Ph 1	Ph 1b	Ph 2	Next milestones
Synthetic cannabidiol	BTX 1503	Moderate to severe acne					Phase 2 clinical study underway
	BTX 1204	Atopic dermatitis					Phase 2 clinical study pending
	BTX 1308	Psoriasis					Phase 1b patient study underway
	BTX 1801	Antimicrobial					Phase 1b patient study
Permetrex™ programs	Internal/external	Various					Ongoing Service fees and potential licenses

Development Pipeline

BTX 1503: acne

BTX 1204: atopic dermatitis


BTX 1308: psoriasis

BTX 1801: antimicrobial

BTX 1503: acne – mechanism of action for acne

BTX 1503 is a safe and well tolerated topical treatment that addresses all 3 key pathologies of acne

CBD addresses multiple pathologies that contribute to acne in a CB1/CB2 independent manner¹



CBD has been shown to...


- ✓ Have anti-inflammatory effects on human sebocytes and to suppress sebocyte proliferation²
- ✓ Have potent anti-microbial activity against gram-positive bacteria³
- ✓ Inhibit human keratinocyte proliferation, through a non CB1/CB2 mechanism⁴

1. Rocha & Bagatin Acne Vulgaris: an Inflammatory Disease Even Before the Onset of Clinical Lesions (2014). *Inflammation and Allergy – Drug Targets* June 13(3); 2. Olah et al. *J Clin Invest.* 2014;124(9):3713-3724; 3. Appendino et al. *J Natl Prod.* 2008;71:1427-1430; 4. Wilkinson & Williamson. *J Derm Sci.* 2007;45:87-92.

BTX 1503: acne – outperforms leading acne products



4 week study data shows a marked reduction in inflammatory lesions, greater than any other FDA approved topical acne product¹

Lesion count reduction (%)



* Day 35 results indicates the reduction effect persists 7 days after the last treatment

Comparison with other FDA approved products

Product	Owner	Lesion count reduction (%) ²	2016 annual revenue ³
 Epiduo®	Galderma	~42%	US\$494m
 Aczone®	Allergan	~38%	US\$456m
BTX 1503	Botanix	~47%	-

- Combination of two drugs – benzoyl peroxide and adapalene
- û Common side effects include redness, skin peeling mild burning / stinging and dryness

- û Few side effects
- û Studies showed large placebo / vehicle effect – i.e. at 12 weeks Aczone reduced inflammatory lesions by 54% while vehicle achieved 48% reduction

1. Botanix Pharmaceuticals data on file. 2. Lesion count reduction based on average inflammatory lesion reduction at 4 weeks. 3. Based on 2016 annual revenue in the US.

BTX 1503: acne – Phase 2 study overview

12-week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1503 in patients with moderate to severe acne

Design

- 5 dose groups: ~360 subjects
 - High Dose twice a day: ~90 subjects
 - High Dose once a day: ~90 subjects
 - Low Dose once a day: ~90 subjects
 - Vehicle/Control: ~90 subjects
- ~28 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate to severe acne patients
- Treatment Period 12 weeks

Endpoints

- Primary endpoints:
 - absolute change from Baseline to Week 12 in inflammatory lesions
- Secondary endpoints:
 - absolute change from Baseline to Week 12 in non-inflammatory lesions
 - % change from Baseline to Week 12 in inflammatory and non-inflammatory lesions
 - proportion of patients with at least 2 grade reduction from Baseline IGA at week 12
- Safety
 - adverse events and local tolerability

Commenced July 2018 (~12 months duration) – fully funded


BTX 1503: acne – next steps

Botanix is pursuing a rapid clinical development strategy to accelerate product commercialisation and timing to first revenues

- Phase 2 clinical study started early 3Q CY2018 and will take approximately 12 months to complete
- Study designed to deliver data that allows licensing and other corporate opportunities

BTX 1503 indicative clinical timeline (CY)


File IND for FDA regulated Phase 2 trial
First patient enrolled in Phase 2 trial
US and Australian sites all activated
Patient enrolment complete



Milestones

BTX 1204: atopic dermatitis – mechanism of action

Atopic dermatitis (and psoriasis) are both T-cell mediated inflammatory diseases of the skin



1. During the “acute phase”, dendritic cells cause excessive Th2 and Th17 cell activation
2. During the “chronic phase”, dendritic cells recruit Th1 cell populations that release Interferon-g

CBD inhibits Th17 responses (IL17), anti-inflammatory effect (*in vitro* model of IL-17A-induced mucosal inflammation using human cells)^{1,2}

CBD attenuates Th2 responses (IL4/IL13), anti-inflammatory effect (in mouse models of AD)^{3,4}

CBD inhibits Interferon-g production which prevents deterioration of skin barrier function (In activated lymphocyte cultures)¹ (mouse model of autoimmune myocarditis)⁵

1. Harvey et al. *Cytokine*. 2014;65:236-244; 2. Kaplan et al. *Biochem Pharmacol*. 2008;76(6):726-737; 3. Gaffal et al. *Exp Derm*. 2014;23:401-406; 4. Kim et al. *Int J Derm*. 2015;54:e410-e408; 5. Lee et al. *Mol Med*. 2016;22:136-146.

BTX 1204: atopic dermatitis – Phase 1b study design

Successful 4-week treatment period, double-blind, vehicle controlled patient study concluded in late May 2018

Design

- ~36 subjects 18 years and older (24 active / 12 vehicle)
- 4 Australian dermatology sites
- BTX 1204 solution BID applied topically
- At least 1 lesion (25 to 200 cm²), on the trunk upper or lower extremities
- Signs of AD score ≥ 6 and ≤ 12
- Investigator's Static Global Assessment (ISGA) of mild (2) or moderate (3)

Endpoints


- Primary endpoints:
 - safety – AEs, labs, local tolerability and signs of atopic dermatitis
- Exploratory endpoints:
 - ISGA
 - target lesion size



Study successfully completed end 2Q CY2018

BTX 1204: atopic dermatitis – Phase 1b study results

BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of AD¹



1. Botanix data on file. Results indicated substantial reduction in key signs of AD, providing confidence that unmet needs in AD can be addressed

2. Treatment success defined as a greater than, or equal to, a 4 point improvement in the signs and symptoms of AD

Key takeaways

Efficacy still increasing at 4 week timepoint

- Achieved treatment success similar to many competitive topical products at the end of their peak treatment period
- Data suggests longer treatment period for BTX 1204 possible for increased efficacy, potentially to exceed industry performance

Clear separation from vehicle (placebo)

- Despite being a small study, BTX 1204 shows superiority over vehicle, starting at early time points
- First vehicle-controlled study for Botanix, which also supports potential for other pipeline products

Excellent safety profile

- Safety and tolerability established with no burning, stinging or application site adverse events
- BTX 1204 profile allows extended dosing which remains a key challenge with most available therapies

BTX 1204: atopic dermatitis – Phase 2 study design

12 week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1204 in patients with moderate AD

Design

- 2 dose groups: ~200 subjects
 - BTX 1204: ~100 subjects
 - Vehicle/Control: ~100 subjects
- ~25 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate AD patients
- Treatment period of 12 weeks

Endpoints

- Primary endpoint:
 - proportion of subjects with ISGA success defined as an ISGA score of “Clear” (0) or “Almost Clear” (1) with at least a 2 grade improvement from Baseline at Week 12
- Secondary endpoints:
 - change from Baseline in the Signs of AD
 - % body surface area (BSA) affected by AD
 - time to achieve IGA success
- Safety
 - adverse events and local tolerability


First patients in 4Q CY2018 – fully funded

BTX 1204: atopic dermatitis – next steps

BTX 1204 complements existing products in development, allowing faster development and transition times through key regulators (FDA and DEA)

- development program leverages existing data from BTX 1503 acne studies, lowering regulatory and safety hurdles
- common usage of DEA licensed dermatology clinics in US from BTX 1503 acne Phase 2 study, reduces cost and start-up timing

BTX 1204 indicative clinical timeline (CY)





★ Milestones

BTX 1308: psoriasis – next steps

Botanix has commenced a Phase 1b study to test BTX 1308 against vehicle and a marketed psoriasis drug in patients

- Novel multi-drug comparison study format in the *same patient*, provides high quality data on BTX 1308 efficacy
- Biopsy data will elucidate MOA and (for the first time) confirm anti-inflammatory and immune modulation activity
- Study de-risks psoriasis indication, as well as provides scientific support to mechanisms for acne and atopic dermatitis

BTX 1801 indicative development timeline (CY)




Bioskin GmbH psoriasis plaque test, including change in infiltrate thickness as measured by sonography

BTX 1801: antimicrobial – results summary

BTX 1801 data demonstrates potential for a new antimicrobial to treat unmet needs in skin infections together with additional benefits seen in prior Botanix studies (e.g. reduction in inflammation)

Summary of data



The study results demonstrate that the delivery of cannabidiol with Permetrex™ can reduce the concentration of the active drug required to achieve the highest levels of bacterial killing

BTX 1801 may have the following benefits

- ü Gram-positive bactericidal effect
- ü New mechanism of action
- ü Active against MRSA
- ü Topical application suited for skin infections
- ü Benign side effect profile based on previous clinical studies
- ü Ability to use long term
- ü Anti-inflammatory and skin barrier improvement properties
- ü Suitable for treatment of children (due to low toxicity)
- ü Prevent early use of IV antibiotics (significant side effects)

Experienced team

Global team with proven experience in dermatology and a track record of securing drug approvals



Mr Matthew Callahan
Founder and Board Executive Director



Corporate + IP

- Developed 3 products to date that have received FDA approval, 1 pending approval
- Ex-investment director of 2 venture capital firms in life sciences
- Serial entrepreneur with extensive product development and launch experience



Dr Michael Thurn
Head Australian Operations



Operations + Regulatory

- Extensive start up life sciences experience across a range of technology platforms
- Previous MD of Spinifex Pharmaceutical, which sold to Novartis for A\$700m



Dr Stephane Levy
Chief Medical Officer



Medical + Clinical

- Ex-CMO of Almirall US operations and VP Sanofi and Novartis
- Broad commercial and clinical development experience



Ms Jillian Chapas Reed
Snr Director Clinical Operations



Clinical

- 20 years clinical trial experience across dermatology and immunology
- Held senior director roles with CRO's companies and hospital sponsors



Dr Judith Plon
VP Regulatory Affairs



Regulatory

- 30 years regulatory experience with multiple FDA approved dermatology products
- Ex-AVP Global Regulatory Affairs at Sanofi



Dr Bill Bosch
Executive Director



Manufacturing + IP


- 6 FDA approved products and inventor of the iCeutica SoluMatrix Technology
- Founder of NanoSystems and co-inventor of drug delivery technology NanoCrystal

Key catalysts

Significant clinical and operational milestones across multiple programs expected over the next 12 months

Indicative activities and milestones

BTX 1503 Acne Phase 2	First patient enrolled in Phase 2 study
	Patient enrolment complete
	Phase 2 multi-centre acne patient clinical study
BTX 1204 Atopic dermatitis Phase 2	Pre-IND Meeting for Phase 2 study
	First patients Phase 2 study
	Phase 2 multi-centre AD patient clinical study
BX 1308 Psoriasis Phase 1b	Phase 1b study in psoriasis patients
BTX 1801 Antimicrobial	Identification of skin disease indication
	Collaboration with University of Queensland
Permetrex™	Research collaborations and partnership discussions



★ Milestones

Contact us

Matt Callahan

Botanix Pharmaceuticals

Founder and Board Executive Director

P: +1 215 767 4184

E: mcallahan@botanixpharma.com

Visit us

www.botanixpharma.com

Follow us on social media



Botanix Pharmaceuticals Limited (ASX:BOT)

